Business
Champions Oncology Reports Revenue of $16.6 Million
Company remains on track to deliver year-over-year revenue growth and positive adjusted EBITDA for the fiscal year HACKENSACK, NJ / ACCESS Newswire / March 12, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research ...
About this update from Champions Oncology, Inc.
[{"type":"text","content":"Company remains on track to deliver year-over-year revenue growth and positive adjusted EBITDA for the fiscal year","length":114,"tagName":"p"},{"type":"text","content":"HACKENSACK, NJ / ACCESS Newswire / March 12, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced its financial results for its third quarter of fiscal 2026, ended January 31, 2026.","length":247,"tagName":"p"},{"type":"text","content":"Third Quarter and Recent Highlights:","length":36,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Record study service revenue of $16.6 million, up approximately 32% year over year","length":82,"tagName":"p"}]},{"val":[{"type":"text","content":"Total revenue of $16.6 million, compared to $17.0 million in the prior-year period","length":82,"tagName":"p"}]},{"val":[{"type":"text","content":"Adjusted EBITDA of $574,000; GAAP loss from operations of approximately $276,000","length":80,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":244,"olType":false},{"type":"text","content":"The Company's third quarter reflected record service revenue driven by strong study execution and the conversion of previously booked work. As is typical in the Company's business, quarterly revenue can fluctuate depending on study timing and completion milestones. The strong third quarter reflects, in part, the conversion of backlog that had been delayed earlier in the year and may normalize somewhat in the near term before continuing to grow as bookings expand.","length":475,"tagName":"p"},{"type":"text","content":"Robert Brainin, CEO of Champions, commented, "We delivered strong operational performance in the third quarter, including another quarter of record study services revenue and our third consecutive quarter of positive adjusted EBITDA. While quarterly results can fluctuate in our business, we remain on track for annual growth and full-year positive adjusted EBIDTA while continuing to invest in our data platform and discovery therapeutics initiatives. We are also encouraged by the early momentum we are beginning to see in our data business and remain confident that our differentiated tumor bank, expanding capabilities, and growing customer engagement position Champions well for long-term growth."","length":712,"tagName":"p"},{"typ...